RT Journal Article
T1 Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C
A1 Diago, M.
A1 Castellano Tortajada, Gregorio
A1 García Samaniego, J.
A1 Pérez, C.
A1 Fernández Vázquez, María Inmaculada
A1 Romero, M.
A1 Iacono, O. L.
A1 García Monzón, C.
AB Background: Increased serum and intrahepatic interferon gamma inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described.Aim: To analyse the possible association of serum IP-10 levels with different outcomes to antiviral therapy.Patients: A total of 137 CHC patients treated with peginterferon plus ribavirin.Methods: Serum IP-10 levels were determined by enzyme linked immunosorbent assay before therapy, after 12 weeks of treatment, and 24 weeks after cessation of therapy. Variables significantly associated with a sustained virological response (SVR) on univariate analysis were included in a multivariate logistic regression model.Results: Pretreatment serum IP-10 levels in patients with SVR were significantly lower than in non-responders (NR) (332.4 (222.1) v 476.8 (305.3) pg/ml, respectively; p=0.004). Serum IP-10 concentrations significantly decreased in patients with SVR (pretreatment: 332.4 (222.1) pg/ml; post-treatment: 170.2 (140.1) pg/ml; p<0.001) but not in NR (pretreatment: 476.8 (305.3) pg/ml; post treatment: 387.3 (268.1) pg/ml; p=0.06). By multivariate analysis, non-1 genotype (odds ratio (OR) 3.5 (95% confidence interval (CI) 1.1-10.4); p=0.003) and low viral load at baseline (OR 0.34 (95% CI 0.14-0.79); p=0.01) were independent predictors of SVR in all patients. When multivariate analysis was restricted to patients with genotype 1, only baseline viral load (OR 0.38 (95% CI 0.155-0.96); p=0.04) and pretreatment serum IP-10 levels (OR 0.99 (95% CI 0.996-0.999); p=0.03) were identified as predictive factors of SVR.Conclusion: Pretreatment serum IP-10 behaves as a predictive factor of SVR to peginterferon plus ribavirin therapy in genotype 1 infected patients.
PB BMJ
SN 0017-5749
YR 2006
FD 2006-03-01
LK https://hdl.handle.net/20.500.14352/114097
UL https://hdl.handle.net/20.500.14352/114097
LA eng
NO Diago M, Castellano G, García-Samaniego J, et alAssociation of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis CGut 2006;55:374-379.
NO Instituto de Salud Carlos III (España)
DS Docta Complutense
RD 6 abr 2025